48
Participants
Start Date
January 31, 2012
Primary Completion Date
June 30, 2013
Study Completion Date
October 31, 2013
EN41-FPA2 HIV vaccine
Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
EN41-FPA2 HIV vaccine
Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
EN41-FPA2 HIV vaccine
Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
EN41-FPA2 HIV vaccine
Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
Na Cl Placebo vaccine
Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
Surrey Clinical Research Centre University of Surrey, Guildford
Lead Sponsor
European Commission
OTHER
PX'Therapeutics
INDUSTRY